TKT and cancer: For example, TK inhibitors (TKIs) have shown little to no clinical efficacy in the treatment of bladder, esophageal, prostate, brain, and stomach cancers.4, 5, 6, 7, 8 While it has been firmly established that aberrant kinase activity indeed leads to cancer progression and metastasis in many cancers, researchers have not fully elucidated the ideal cancer-specific kinase targets or novel drug combinations to improve the standard of care.